Ioxilan
Identification
- Summary
Ioxilan is a diagnostic contrast agent used in various medical imaging procedures, such as angiography, urography, and computed tomographic scans.
- Generic Name
- Ioxilan
- DrugBank Accession Number
- DB09135
- Background
Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 791.116
Monoisotopic: 790.86975 - Chemical Formula
- C18H24I3N3O8
- Synonyms
- Ioxilan
- Ioxilane
- Ioxilanum
- N-(2,3-dihydroxypropyl)-N’-(2- hydroxyethyl)-5-[N-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide
- External IDs
- CCRIS 6727
- CID3743
- LS-29720
- MOLI00098
Pharmacology
- Indication
When administered intra-arterially, Ioxilan is indicated for the following diagnostic tests: cerebral arteriography (300 mgI/mL), coronary arteriography and left ventriculography (350 mgI/mL), visceral angiography(350 mgI/mL), aortography(350 mgI/mL), and peripheral arteriography(350 mgI/mL). When administered intravenously, Ioxilan is indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300 and 350 mgI/mL).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
As with other iodinated contrast agents the degree of contrast enhancement is directly related to the iodine content in the administered dose.
- Mechanism of action
Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs.
- Absorption
Peak iodine plasma levels occur immediately following rapid intravenous injection. Iodine plasma levels fall rapidly within 5 to 10 minutes. This can be accounted for by the dilution in the vascular and extravascular fluid compartments.
- Volume of distribution
Ioxilan is distributed mainly in the blood as suggested by the apparent volume of distribution (central compartment), 7.2 ± 1.0 L in women and 10.0 ± 2.4 L in men
- Protein binding
Binding of ioxilan to plasma protein is negligible.
- Metabolism
There is no evidence for metabolism.
- Route of elimination
The average amount of ioxilan excreted unchanged in urine at 24 hours represents 93.7% of the dose in young healthy subjects (21-27 years) after intravenous administration. This finding suggests that, compared to the renal excretion, biliary and/or gastrointestinal excretion are not important.
- Half-life
An initial fast distribution phase with a half-life of 13.1 ± 4.2 minutes (women) or 23.5 ± 15.3 minutes (men) was followed by an elimination phase with a half-life of 102.0 ± 16.9 minutes (women) and 137 ± 35.4 minutes (men).
- Clearance
The total clearance values were 95.4 ± 11.1 mL·min-1 and 101.0 ± 14.7 mL·min-1 and the renal clearance values were 89.4 ± 13.3 mL·min-1 and 94.9 ± 16.6 mL·min-1 for women and men, respectively.
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravascular contrast agents. Administration of any intravascular contrast agent should therefore be postponed in any patient with a known or suspected hepatic or biliary disorder who has recently received a cholecystographic contrast agent.
Other drugs should not be admixed with this product.
Pregnancy Category B
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Ioxilan which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Ioxilan which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Ioxilan which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Ioxilan which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Oxilan Injection, solution 350 mg/1mL Intravascular Guerbet 2002-03-18 2017-10-31 US Oxilan Injection, solution 300 mg/1mL Intravascular Guerbet 2002-03-18 2017-10-31 US
Categories
- ATC Codes
- V08AB12 — Ioxilan
- Drug Categories
- Acids, Carbocyclic
- Benzene Derivatives
- Benzoates
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Iodinated Contrast Agents
- Iodobenzoates
- Radiographic Contrast Agent
- Triiodobenzoic Acids
- Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
- X-Ray Contrast Activity
- X-Ray Contrast Media, Iodinated
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acylaminobenzoic acid and derivatives. These are derivatives of amino benzoic acid derivatives where the amine group is N-acylated.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Acylaminobenzoic acid and derivatives
- Alternative Parents
- O-haloacetanilides / P-haloacetanilides / 2-halobenzoic acids and derivatives / 4-halobenzoic acids and derivatives / Benzamides / Benzoyl derivatives / N-acylethanolamines / Iodobenzenes / Aryl iodides / Tertiary carboxylic acid amides show 10 more
- Substituents
- 2-halobenzoic acid or derivatives / 4-halobenzoic acid or derivatives / Acetamide / Acetanilide / Acylaminobenzoic acid or derivatives / Alcohol / Alkanolamine / Anilide / Aromatic homomonocyclic compound / Aryl halide show 27 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- A4YJ7J11TG
- CAS number
- 107793-72-6
- InChI Key
- UUMLTINZBQPNGF-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)
- IUPAC Name
- N1-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-N3-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
- SMILES
- CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I
References
- General References
- Not Available
- External Links
- KEGG Drug
- D02161
- PubChem Compound
- 3743
- PubChem Substance
- 310265050
- ChemSpider
- 3612
- 27793
- ChEBI
- 135884
- ChEMBL
- CHEMBL1201075
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Ioxilan
- FDA label
- Download (3.16 MB)
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravascular 300 mg/1mL Injection, solution Intravascular 350 mg/1mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.559 mg/mL ALOGPS logP -2.5 ALOGPS logP -1.3 Chemaxon logS -3.2 ALOGPS pKa (Strongest Acidic) 11.74 Chemaxon pKa (Strongest Basic) -1.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 179.66 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 142.88 m3·mol-1 Chemaxon Polarizability 57.05 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 219.54736 predictedDeepCCS 1.0 (2019) [M+H]+ 221.90535 predictedDeepCCS 1.0 (2019) [M+Na]+ 227.99849 predictedDeepCCS 1.0 (2019)
Drug created at September 29, 2015 22:16 / Updated at February 21, 2021 18:52